自10月24日以来公司已连续27日进行回购，合计回购1.93亿股，累计回购金额8.24亿港元。 其间该股累 计上涨4.48%。 （原标题：中国飞鹤(06186.HK)连续27日回购，累计回购1.93亿股） 证券时报•数据宝统计，中国飞鹤在港交所公告显示，12月2日以每股4.170港元至4.200港元的价格回购 400.00万股，回购金额达1674.00万港元。该股当日收盘价4.200港元，平盘报收，全天成交额7219.58万 港元。 中国飞鹤回购明细 | 日期 | 回购股数 | 回购最高价 | 回购最低价 | 回购金额 | | --- | --- | --- | --- | --- | | | （万股） | （港元） | （港元） | （万港元） | | 2025.12.02 | 400.00 | 4.200 | 4.170 | 1674.00 | | 2025.12.01 | 150.00 | 4.230 | 4.190 | 631.65 | | 2025.11.28 | 230.00 | 4.220 | 4.150 | 958.58 | | 2025.11.27 | 400.00 | 4.230 | 4. ...

Core Viewpoint - Longbai Group has made significant progress in its share repurchase plan, having repurchased shares worth approximately 25.48 million yuan as of November 30, 2025, which aligns with its established plan and regulatory requirements [1][3]. Summary by Sections Share Repurchase Plan Overview - On June 6, 2025, Longbai Group's board approved a share repurchase plan, intending to use its own funds and special loans to repurchase A-shares for employee stock ownership plans [2]. - The plan has a total funding range of 5 billion yuan to 10 billion yuan, with a maximum repurchase price set at 24.32 yuan per share, and is to be executed within 12 months from the board's approval [2]. Progress of Share Repurchase - As of November 30, 2025, Longbai Group has repurchased shares at a minimum price of 16.18 yuan per share, totaling approximately 25.48 million yuan (excluding transaction fees) [3]. - The repurchase is in compliance with relevant regulations and aligns with the company's established repurchase plan [3]. Compliance and Regulatory Adherence - Longbai Group emphasizes strict adherence to regulatory requirements during the share repurchase, ensuring that repurchases do not occur during periods that could significantly impact stock prices [4]. - The company has complied with trading regulations, ensuring that the repurchase prices were not set at the daily trading limit and did not occur during restricted trading periods [4]. Future Plans - The company plans to continue its share repurchase efforts within the 12-month timeframe, adjusting based on market conditions and operational performance [5]. - Longbai Group has utilized approximately 5.1% of the lower limit of the repurchase funds (based on the 5 billion yuan minimum) and will maintain transparency in its repurchase process [5].

长虹美菱公告，截至2025年11月30日，公司通过股票回购专用证券账户以集中竞价交易方式回购公司A 股1031.47万股，占公司总股本的1.0015%；本次回购A股股份最高成交价为7.45元/股，最低成交价为 6.58元/股，成交总金额为7263.06万元（不含交易费用）。 ...

Core Viewpoint - The company, Giant Bio (02367.HK), has announced a large-scale share buyback plan, which has positively impacted its stock price and market perception, reflecting investor confidence in its future development [1][9]. Company Performance - Giant Bio is a leading player in the recombinant collagen market, with its products being widely used in popular beauty products. The company has been recognized as a global leader in recombinant collagen by authoritative market research institutions [2][10]. - For the first half of the year, Giant Bio reported a revenue of 31.13 billion RMB, a year-on-year increase of 22.5%. Gross profit was 25.42 billion RMB, up 21.5%, and net profit reached 11.82 billion RMB, growing by 20.6% [2][10]. Stock Price Dynamics - Since May, the stock price of Giant Bio has been on a downward trend, losing nearly half of its value from its peak. This decline was partly due to negative publicity regarding the collagen content in its products, leading to a public relations crisis [3][11]. - The company's brand, Kefu Mei, experienced a decline in GMV during the Double Eleven shopping festival, raising concerns about consumer acceptance and impacting the stock price further [3][11]. Share Buyback Plan - In response to the stock price decline, Giant Bio announced a buyback plan to repurchase up to approximately 104 million shares, representing 10% of its total issued shares. This move is seen as a sign of management's confidence in the company's intrinsic value and commitment to optimizing capital structure [4][12]. - Large-scale buybacks are typically viewed as a signal that a company's stock is undervalued and indicate strong cash flow and stable operations [6][14]. Market Outlook - Despite current challenges in the consumer market, Giant Bio is considered competitive in product development, channel construction, and brand building. The buyback action is expected to enhance market perception of its operational stability and long-term growth potential [6][14]. - Analysts remain optimistic about the company's future performance, projecting net profits of 24.3 billion RMB, 29.8 billion RMB, and 36.4 billion RMB for 2025-2027, with corresponding P/E ratios of 15X, 12X, and 10X [15].

Core Points - Hangzhou Minsheng Health Pharmaceutical Co., Ltd. has announced the progress of its second share repurchase plan, revealing that as of November 30, 2025, no shares have been repurchased, representing 0.00% of the company's total share capital [1][3] Summary by Sections Repurchase Plan Overview - The second share repurchase plan was approved by the company's board on October 28, 2025, with a maximum repurchase price set at 21.06 CNY per share, which is 150% of the average trading price over the previous 30 trading days [2] - The expected number of shares to be repurchased ranges from 2.1 million to 2.4 million shares, with a total estimated repurchase fund not exceeding 50.544 million CNY [2] Implementation Progress - As of November 30, 2025, the company has not conducted any repurchase operations, citing market conditions as the reason for the lack of activity [3] - The company is adhering to regulations regarding share repurchases, including avoiding repurchases during significant market events or periods prohibited by regulatory authorities [3] Future Plans - The company intends to continue pursuing the repurchase plan within the designated timeframe and will fulfill its information disclosure obligations as required by law [4] - The implementation of the repurchase plan may face uncertainties, and the company has previously disclosed multiple share repurchase plans, indicating ongoing market interest [4]

北京商报讯（记者 刘宇阳）12月2日，国投资本发布关于以集中竞价交易方式回购公司股份的进展公告。公告显示，截 至11月28日，公司已累计回购股份45.61万股，占公司总股本的比例为0.0071%，购买的最高价为7.71元/股，最低价为 7.58元/股，已支付的总金额约为349.93万元（不含交易费用）。 回顾2025年4月9日，国投资本召开董事会审议通过了《关于以集中竞价交易方式回购公司A股股份的议案》，同意公司 以集中竞价交易方式回购公司发行的部分人民币普通股（A股），回购资金总额不低于人民币2亿元（含），不超过人 民币4亿元（含），回购股份实施期限为自公司董事会审议通过该次回购股份方案之日起12个月内。 | 回购方案首次披露日 | 2025/4/10 | | --- | --- | | 回购方案实施期限 | 2025年4月9日~2026年4月8日 | | 预计回购金额 | 20,000万元~40,000万元 | | 回购用途 | □减少注册资本 | | | □用于员工持股计划或股权激励 | | | √用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 456.100股 ...

格隆汇12月2日｜天合光能公告称，公司于2024年6月25日开启回购，原计划2025年6月24日止，后延期 至2026年3月24日，资金来源调整为自有和自筹资金。预计回购1亿 - 1.2亿元股份用于转换可转债。截 至2025年11月30日，累计回购3737.7953万股，占总股本1.60%，成交最高价24.91元/股，最低价13.64元/ 股，支付资金6.92亿元。 ...

九源基因(02566)公布，董事会于2025年12月2日议决，视乎市况，公司拟根据购回授权，自本公告日期 起至购回授权届满止期间，使用最多人民币1亿元于公开市场以自有资金购回最多约1090.97万股H股。 每次购回的每股H股的实际购回价比紧随每次购回前五个交易日内H股股份平均收市价溢价不得高于5% 或以上。根据购回授权进行购回的H股股份将可能会被注销、持作库存股份或用于股份激励计划。 公司现时现金流量稳健，整体财务状况稳定，可满足公司业务持续发展的需求。董事会认为，当前的股 份成交价格并未充分反映公司的内在价值及业务前景，于现况下进行股份购回将彰显公司及管理层团队 对公司的业务发展前景及增长潜力充满信心，最终会为公司带来裨益并为股东创造价值。 ...

中远海控（601919）(601919.SH)发布公告，截至2025年11月30日，公司通过上海证券交易所交易系统 以集中竞价交易方式累计回购A股股份约5000万股，占公司截至2025年11月30日总股本的比例为 0.323%，购买的最高价为人民币14.98元/股、最低价为人民币14.86元/股，已支付的总金额为人民币7.48 亿元(不含交易费用)。 ...

蓝思科技12月2日公告，公司于2025年4月7日召开第五届董事会第四次会议，审议通过了《关于回购公 司股份方案的议案》，同意公司使用自有资金或自筹资金以集中竞价交易方式，回购公司部分已发行的 普通股（Ａ股）股份，用于实施员工持股计划或股权激励计划。本次回购金额不低于5亿元（含）且不 超过10亿元（含），回购股份价格上限为34.5元/股，回购股份期限为自公司董事会审议通过本次回购 股份方案之日起12个月内。截至2025年11月30日，公司累计回购730.96万股，占公司总股本的0.15%， 回购价格区间为22.5元/股至30.24元/股，累计使用资金2.12亿元（不含交易费用）。 ...